Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

ClinicalTrials.gov ID: NCT03759340

Public ClinicalTrials.gov record NCT03759340. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label Study of ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Study identification

NCT ID
NCT03759340
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Enrollment
56 participants

Conditions and interventions

Interventions

  • ATI 502 0.46% Topical Solution Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 14, 2019
Primary completion
Sep 10, 2019
Completion
Sep 10, 2019
Last update posted
Oct 5, 2020

2019

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Aclaris Investigator Site Rogers Arkansas 72758
Aclaris Investigator Site Denver Colorado 80210
Aclaris Investigator Site Boynton Beach Florida 33472
Aclaris Investigator Site Snellville Georgia 30078
Aclaris Investigator Site Clinton Township Michigan 48038
Aclaris Investigator SIte Detroit Michigan 48202
Aclaris Investigator Site Fridley Minnesota 55432
Aclaris Investigator Site Minneapolis Minnesota 55455
Aclaris Investigator Site Saint Joseph Missouri 64506
Aclaris Investigator Site Omaha Nebraska 68144
Aclaris Investigator Site Las Vegas Nevada 89148
Aclaris Investigator Site New York New York 10075
Aclaris Investigator Site Rochester New York 14623
Aclaris Investigator Site Portland Oregon 97223
Aclaris Investigator Site Greenville South Carolina 29607
Aclaris Investigator Site Knoxville Tennessee 37922
Aclaris Investigational Site Nashville Tennessee 37215
Aclaris Investigational Site Austin Texas 78745
Aclaris Investigator Site Houston Texas 77056
Aclaris Investigator Site Lynchburg Virginia 24501

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03759340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2020 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03759340 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →